Related Experiment Video
Updated: Jan 25, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
B7-H3 and its role in bone cancers
1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
B7-H3 is a promising target for bone cancer immunotherapy. Research shows its potential in osteosarcoma and myeloma, with ongoing clinical trials exploring B7-H3 targeted therapies for improved outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Bone cancers often exhibit high metastasis and recurrence rates, necessitating novel therapeutic strategies beyond conventional treatments.
- While checkpoint immunotherapies show promise, the role of B7-H3 (CD276), a B7-family molecule, remains underexplored in bone malignancies.
- Existing treatments for bone cancers have limitations, creating an urgent need for innovative and effective therapeutic approaches.
Purpose of the Study:
- To review and summarize current research on the expression and therapeutic targeting of B7-H3 in various bone cancers.
- To identify the unmet needs and potential of B7-H3 as a novel immunotherapeutic target in bone oncology.
Main Methods:
- Literature review of studies investigating B7-H3 expression in osteosarcoma, chondrosarcoma, Ewing's sarcoma, myeloma, osteoclastoma, and chordoma.
- Analysis of research exploring B7-H3 targeted immunotherapies, including chimeric antigen receptor (CAR) T-cells and antibody-based treatments.
- Inclusion of data from preclinical studies and ongoing clinical trials evaluating B7-H3 as a therapeutic target.
Main Results:
- B7-H3 expression has been investigated in osteosarcoma, myeloma, osteoclastoma, and chordoma, with limited research in chondrosarcoma.
- Preclinical studies demonstrate the potential of targeting B7-H3 using CAR T-cells and antibodies in Ewing's sarcoma and myeloma.
- Two clinical trials are currently underway to evaluate B7-H3 as a therapeutic target in osteosarcoma and myeloma.
Conclusions:
- B7-H3 represents a potential therapeutic target for several types of bone cancer.
- Further research and clinical investigation are warranted to fully elucidate the role of B7-H3 in bone cancer and its therapeutic efficacy.
Related Concept Videos
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture
Role of Hippocampus in Memory
Role-Based Identity
Role of ER in the Secretory Pathway
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...

